Qian Geng1, Haoyu Peng1, Fengsheng Chen1, Rongcheng Luo1, Rong Li2. 1. Cancer Center, Southern Medical University Guangzhou 510315, China ; Traditional Chinese Medicine-Integrated Hospital, Southern Medical University Guangzhou 510315, China. 2. Cancer Center, Southern Medical University Guangzhou 510315, China ; Department of Oncology, Nanfang Hospital, Southern Medical University Guangzhou 510515, China.
Abstract
OBJECTIVE: Sirt7, as one of the seven Sirtuin family members, which plays distinct roles in cancer progression, is bringing emerging attention due to its oncogenic characteristic. The expression of Sirt7 in breast cancer remained unclear, and the aim of this study was to elucidate its role in breast cancer. METHODS: A total of 188 cases included in this study were immunohistochemically evaluated for Sirt7, and western blot assay was used to assess its expression in breast cell lines as well as 36 breast cancer tissues and 36 paired non-cancerous tissues. RESULTS: Upregulation of Sirt7 was found in breast cancer cell lines and breast cancer tissues (P < 0.001) by western blot analysis. Sirt7 was highly expressed in breast cancer tissue samples (67.8%) compared to adjacent normal breast tissues (31.8%) by immunohistochemical assay. It was also observed that the high expression level of Sirt7 was significantly correlated with high histological grade (P = 0.039) and negatively related to overall survival (P = 0.006). Sirt7 proved to be an independent prognostic factor (P = 0.007) in breast cancer. CONCLUSIONS: Sirt7 expression was implicated with high histological grade and independently predicted poor clinical outcome in patients with breast cancer, suggesting that Sirt7 might play a role in the malignant progression of breast cancer.
OBJECTIVE:Sirt7, as one of the seven Sirtuin family members, which plays distinct roles in cancer progression, is bringing emerging attention due to its oncogenic characteristic. The expression of Sirt7 in breast cancer remained unclear, and the aim of this study was to elucidate its role in breast cancer. METHODS: A total of 188 cases included in this study were immunohistochemically evaluated for Sirt7, and western blot assay was used to assess its expression in breast cell lines as well as 36 breast cancer tissues and 36 paired non-cancerous tissues. RESULTS: Upregulation of Sirt7 was found in breast cancer cell lines and breast cancer tissues (P < 0.001) by western blot analysis. Sirt7 was highly expressed in breast cancer tissue samples (67.8%) compared to adjacent normal breast tissues (31.8%) by immunohistochemical assay. It was also observed that the high expression level of Sirt7 was significantly correlated with high histological grade (P = 0.039) and negatively related to overall survival (P = 0.006). Sirt7 proved to be an independent prognostic factor (P = 0.007) in breast cancer. CONCLUSIONS:Sirt7 expression was implicated with high histological grade and independently predicted poor clinical outcome in patients with breast cancer, suggesting that Sirt7 might play a role in the malignant progression of breast cancer.
Entities:
Keywords:
Breast cancer; immunohistochemistry; oncogenes; tumour markers
Authors: Jeong Kyu Kim; Ji Heon Noh; Kwang Hwa Jung; Jung Woo Eun; Hyun Jin Bae; Min Gyu Kim; Young Gyoon Chang; Qingyu Shen; Won Sang Park; Jung Young Lee; Jürgen Borlak; Suk Woo Nam Journal: Hepatology Date: 2013-02-11 Impact factor: 17.425
Authors: Olesya Vakhrusheva; Christian Smolka; Praveen Gajawada; Sawa Kostin; Thomas Boettger; Thomas Kubin; Thomas Braun; Eva Bober Journal: Circ Res Date: 2008-01-31 Impact factor: 17.367
Authors: Santina Bruzzone; Marco Daniele Parenti; Alessia Grozio; Alberto Ballestrero; Inga Bauer; Alberto Del Rio; Alessio Nencioni Journal: Curr Pharm Des Date: 2013 Impact factor: 3.116
Authors: Wesley Wei Wang; Maria Angulo-Ibanez; Jie Lyu; Yadagiri Kurra; Zhen Tong; Bo Wu; Ling Zhang; Vangmayee Sharma; Jennifer Zhou; Hening Lin; Yi Qin Gao; Wei Li; Katrin F Chua; Wenshe Ray Liu Journal: J Am Chem Soc Date: 2019-02-04 Impact factor: 15.419